Biogen Idec

Biogen Idec to acquire Convergence Pharmaceuticals, expands neuropathic pain portfolio

Tuesday, January 13, 2015 09:30 AM

Biogen Idec has agreed to acquire U.K.-based Convergence Pharmaceuticals, a clinical-stage biopharmaceutical company with an innovative portfolio of ion channel-modulating product candidates for neuropathic pain. Biogen Idec plans to leverage Convergence’s experience in chronic pain research and clinical development to accelerate the growth of its pain portfolio.

More... »


ALS Association awards research funds for C9orf72 clinical trials

Friday, December 12, 2014 03:34 PM

The ALS Association, a national nonprofit organization based in Wash. D.C., has awarded $326,662 in research funds to expand ongoing natural history studies in order to further understand the most common genetic cause of ALS, in preparation for clinical trials in those whose disease is affected by this gene.

More... »


Cubist Pharmaceuticals names Robert J. Perez CEO

Thursday, October 23, 2014 03:47 PM

Cubist Pharmaceuticals has selected Robert J. Perez as the company's CEO, effective January, 2015. Perez, who currently is Cubist's president and chief operating officer, will succeed Michael W. Bonney who is retiring from his current role as CEO on Dec. 31, and will become non-executive chair of Cubist's board of directors. Current board chair Kenneth M. Bate will become lead independent director.

More... »

FDA approves Biogen Idec’s Plegridy for multiple sclerosis

Monday, August 18, 2014 09:13 AM

The FDA has approved Biogen Idec’s Plegridy (peginterferon beta-1a), a new treatment for people with relapsing forms of multiple sclerosis (RMS). Plegridy, the only pegylated beta interferon approved for use in RMS, is dosed once every two weeks and can be administered subcutaneously with the Plegridy Pen, a new, ready-to-use autoinjector, or a prefilled syringe.

More... »

Regulus Therapeutics, Biogen Idec collaborate for multiple sclerosis biomarkers

Wednesday, August 6, 2014 12:58 PM

Regulus Therapeutics, a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, has entered into a new collaboration agreement with Biogen Idec to expand its research focused on identifying microRNAs as biomarkers for multiple sclerosis (MS) under its Regulus microMarkers division. The new research will focus on profiling a large number of whole blood samples from a cohort of MS patients who have been treated with a Biogen Idec MS therapy to identify potential microRNA signatures. 

More... »

FDA approves antihemophilic factor, Fc fusion protein hemophilia A

Thursday, June 12, 2014 11:33 AM

The FDA has approved Eloctate, Antihemophilic Factor (Recombinant), Fc fusion protein, for use in adults and children who have hemophilia A. Eloctate is the first hemophilia A treatment designed to require less frequent injections when used to prevent or reduce the frequency of bleeding.

More... »

Pulmonary Fibrosis Foundation, Biogen Idec partner on PFF Patient Registry

Wednesday, June 11, 2014 12:44 PM

The Pulmonary Fibrosis Foundation (PFF) has partnered with Biogen Idec to support the PFF Patient Registry.

More... »

DrugDev acquires TrialNetworks

Monday, May 5, 2014 10:13 AM

DrugDev, a global network of active clinical trial doctors, has acquired Newton, Mass.-based TrialNetworks. TrialNetworks joins an expanding group of technology-driven solutions to help sponsors, CROs and sites do more trials together.

More... »

Quintiles, Biogen Idec ink 5-year partnership

Thursday, April 24, 2014 01:04 PM

CRO Quintiles and Biogen Idec have entered into a five-year strategic clinical development agreement. The collaboration is designed to leverage the expertise and experience from both organizations to optimize Biogen Idec’s clinical development processes.

More... »

Ian Read becomes PhRMA board chairman; Ken Frazier, George Scangos on board

Friday, April 18, 2014 10:37 AM

Ian C. Read, chairman and CEO of Pfizer, was elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA). Read succeeds Robert J. Hugin, chairman and CEO of Celgene, as PhRMA's chairman. Also elected were Kenneth C. Frazier, chairman, president and CEO of Merck, as chairman-elect of the PhRMA board of directors, and George A. Scangos, Ph.D., CEO of Biogen Idec, as board treasurer.

More... »

CenterWatch Data Library
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs